Strong Buy Rating for Roivant Sciences Backed by Strategic …
WEB2 days ago · Considering that peak sales for Vtama are estimated to be around $1.4 billion by 2036, this creates a significant long-term value proposition for Roivant Sciences.
Organon makes $1.2bn play for Roivant’s immuno-dermatology …
WEB1 day ago · In this article: Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant in a potential $1.2bn deal. Organon will pay $175m upfront for the business as part of the ...
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon …
WEB3 days ago · Psoriasis is a common chronic inflammatory skin disease affecting over 8 million Americans 20 years or older and 125 million people worldwide. Organon has agreed to acquire Dermavant for aggregate ...
News & Press Releases | Roivant
WEBJul 19, 2024 · Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study. Read the full article here. Roivant stock is nearing a breakout Tuesday after the biotech company announced positive results in an eye-disease study and a $1.5 billion share repurchase.
Roivant sells dermatology spinoff to Organon in deal worth $1.2 …
WEB2 days ago · Roivant Sciences continues its dealmaking hot streak, announcing Wednesday that it would sell one of its subsidiaries to pharma company Organon in a deal worth $1.2 billion. ... The news from ESMO ...
Roivant Unveils New Pipeline Program Mosliciguat, A Potential …
WEBSep 10, 2024 · Roivant created Pulmovant, a wholly-owned Roivant subsidiary, to in-license from Bayer exclusive worldwide rights to develop and commercialize mosliciguat. Bayer received an upfront cash payment of ~$14.0 million, with up to an additional $280 million agreed upon for future development, regulatory and commercial milestone payments, as well as ...
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed ...
WEBSep 10, 2024 · Tuesday, Roivant Sciences Ltd. (NASDAQ:ROIV) created Pulmovant to in-license from Bayer AG (OTC:BAYRY) exclusive worldwide rights to develop and commercialize mosliciguat. Bayer received an ...
Roche Completes Acquisition of Telavant from Roivant, Including …
WEBDec 14, 2023 · BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upfront payment of approximately $7.1 billion.
Press Release - Roivant Sciences Ltd.
WEBOct 23, 2023 · BASEL, Switzerland and LONDON and NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the entry into a definitive agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc.
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to …
WEB3 days ago · Resize. By Colin Kellaher. Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on ...